|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Aduro Biotech (ADRO)
CHAIKIN MONEY FLOW
Trading: HOLD @ $2.97
Signal Strength: MEDIUM
Aduro Biotech (NASDAQ:ADRO) current price has highlighted recent buying pressure and the continuation of a bullish trading conditions. Currently, the CMF is 0.35. ADRO received a confirmed CMF crossover days on the Jan 31 2020. The bullish signal has been active for 0 day. During the quarter, the highest CMF value was 0.46 occurring on the Jan 31 2020.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.
Developed by Marc Chaikin, Chaikin Money Flow measures the amount of Money Flow Volume over a specific period. Money Flow Volume forms the basis for the Accumulation Distribution Line. Instead of a cumulative total of Money Flow Volume, Chaikin Money Flow simply sums Money Flow Volume for a specific look-back period, typically 20 or 21 days. The resulting indicator fluctuates above/below the zero line just like an oscillator. Chartists weigh the balance of buying or selling pressure with the absolute level of Chaikin Money Flow. Chartists can also look for crosses above or below the zero line to identify changes on money flow.
Calculation: Chaikin Money Flow (20):
1) Money Flow Multiplier = [(Close - Low) - (High - Close)] / (High - Low);
2) Money Flow Volume = Money Flow Multiplier x Volume for the Period;
3) 20-period CMF = 20-period Sum of Money Flow Volume / 20 period Sum of Volume;
PROFILE: Aduro Biotech (ADRO)
Stock Exchange: NASDAQ
Company: Aduro Biotech
Ticker Codes: | ADRO | NASDAQ:ADRO |
Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer. Its products pipeline also comprises BION-1301, a B-select monoclonal antibody novel therapy for multiple myeloma; A PRoliferation-Inducing Ligand for the treatment of multiple myeloma, chronic lymphocytic leukemia, and colorectal carcinoma; CD27, a co-stimulatory receptor for the treatment of cancer; and CTLA-4 for the treatment of advanced melanoma and other cancers. The company's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neo antigens that are specific to an individual patient's tumor. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Janssen Biotech, Inc, and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
|SYRS Syros Pharmaceuticals||6.65||3.3||129,382||-0.2||BEARISH CROSSOVER|
|SBLK Star Bulk Carriers||8.18||2.1||545,828||-0.02||BEARISH CROSSOVER|
|SGRY Surgery Partners Cs||17.16||1.6||362,415||-0.01||BEARISH CROSSOVER|
|RRGB Red Robin Gourm||26.75||1.3||362,468||-0.03||BEARISH CROSSOVER|
|KLAC KLA-Tencor Corporation||147.99||0.5||3,537,878||-0.02||BEARISH CROSSOVER|
|GTLS Chart Industries||56.83||-0.2||844,419||-0.01||BEARISH CROSSOVER|
|HEES H&E Equip Services||23.47||-0.2||316,704||-0.02||BEARISH CROSSOVER|
|GT Goodyear Tire Rubber||9.91||-1.1||6,649,543||-0.02||BEARISH CROSSOVER|
|PDFS Pdf Solutions Inc||14.53||-1.2||131,490||-0.02||BEARISH CROSSOVER|
|MIDD Middleby Corp||113.56||-1.5||704,136||-0.01||BEARISH CROSSOVER|